News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–38
- Matches
- 38
- Sources here
- 2
- Companies here
- 1
Search results
Stored financial headlines
Active search
38 matching headlines
Ticker or company: TRDAMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10
Roth MKM has reiterated its Buy rating for Entrada Therapeutics (TRDA.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.
TRDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +21.5%